Rayno Life Science Portfolio:Gen-Probe(GPRO) Files PMA Application for HPV
Gen-Probe (GPRO,$51.60) announced yesterday that it submitted a Premarket Approval Application(PMA) the the FDA for its APTIMA HPV (human papillomavirus ) assay , a molecular diagnostic test that detects high-risk HPV infections that are associated with cervical cancer and precancerous lesions....
Cepheid (CPHD) GeneXpert TB Test in India
"A Deadly Misdiagnosis" by Michael Specter An interesting article in the November 15 New Yorker on the Tuberculosis epidemic in India stresses the need for more accurate diagnostic tests and how the Cepheid TB assay can save lives. The author reports on the complexity and economics of India's...
Biomarkers and Blood Screening Tests: GenProbe (GPRO) and Genzyme(GENZ)
Here are some relevant news in areas that we previously covered: Biomarkers Genzyme (GENZ) licensed a lung cancer test under development to Roche and can target a patient's response to their Tarceva cancer drug. The goal is a test for epidermal growth- factor receptor (EGFR) mutations that...
Market Ignores Bad News, Rallies on Retail Outlook
The market overcame bad news for Ireland and European debt, insider trading investigations , Korean crisis and a weak housing market for an S&P rally of 1.49%. NASDAQ is doing even better up 1.93% boosted by Apple (AAPL $315) up 2% and Amazon(AMZN $177) up 5.5%. Most retail stocks lead the...
Rayno Life Science Portfolio: Regeneron(REGN)up 14% on Eye Drug Phase 3 Results
Regeneron(REGN $28) stock soared today on two parallel Phase 3 studies with patients who had neovascular age related macular degeneration(wet AMD), the VEGF Trap Eye drug successfully met the endpoint compared to the current standard of care, ranibizumab dosed every month.Regeneron and its...